Artificial intelligence in hematology

A Aziz Nazha (1Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA) O Olivier Elemento S Sanjay Ahuja (3Innovative Hematology/Indiana Hemophilia and Thrombosis Center, Indianapolis, IN) B Barbara Lam (4Division of Hematology and Oncology, Department of Medicine, Fred Hutchinson Cancer Center, University of Washington Medical Center, Seattle, WA) M Moses Miles (5American Thrombosis and Hemostasis Network, Rochester, NY) R Roni Shouval (1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY) S Shannon McWeeney S Shireen Sirhan (9Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada) A Andrew Srisuwananukorn (10Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH) T Torsten Haferlach (7Munich Leukemia Laboratory, Munich, Germany)

Abstract

Abstract Artificial intelligence (AI) and its subdiscipline, machine learning (ML), have the potential to revolutionize health care, including hematology. The diagnosis and treatment of hematologic disorders depend on the integration of diverse data sources, such as imaging, pathology, omics, and laboratory parameters. The increasing volume and complexity of patient data have made clinical decision-making more challenging. AI/ML hold significant potential for enhancing diagnostic accuracy, risk stratification, and treatment response prediction through advanced modeling techniques. Generative AI, a recent advancement within the broader field of AI, is poised to have a profound impact on health care and hematology. Generative AI can enhance the development of novel therapeutic strategies, improve diagnostic workflows by generating high-fidelity images or pathology reports, and facilitate more personalized approaches to patient management. Its ability to augment clinical decision-making and streamline research represents a significant leap forward in the field. However, despite this potential, few AI/ML tools have been fully implemented in clinical practice due to challenges related to data quality, equity, advanced infrastructure, and the establishment of robust evaluation metrics. Despite its promise, AI implementation in hematology faces critical challenges, including bias, data quality issues, and a lack of regulatory frameworks and safety standards that keep pace with rapid technological advancements. In this review, we provide an overview of the current state of AI/ML in hematology as of 2025, identify existing gaps, and offer insights into future developments.

Article Details

Journal Blood
Volume / Issue Vol. 146, Issue 19
Published November 06, 2025
Pages 2283-2292
ISSN 0006-4971
Publisher Elsevier BV

Journal Info

Blood

Elsevier BV

ISSN: 0006-4971 Health Sciences

Authors (10)

A

Aziz Nazha

1Department of Medical Oncology, Sidney Kimmel Cancer Center, Thomas Jefferson University, Philadelphia, PA

O

Olivier Elemento

S

Sanjay Ahuja

3Innovative Hematology/Indiana Hemophilia and Thrombosis Center, Indianapolis, IN

B

Barbara Lam

4Division of Hematology and Oncology, Department of Medicine, Fred Hutchinson Cancer Center, University of Washington Medical Center, Seattle, WA

M

Moses Miles

5American Thrombosis and Hemostasis Network, Rochester, NY

R

Roni Shouval

1Adult Bone Marrow Transplantation Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

S

Shannon McWeeney

S

Shireen Sirhan

9Segal Cancer Centre, Jewish General Hospital, McGill University, Montreal, QC, Canada

A

Andrew Srisuwananukorn

10Division of Hematology, Department of Internal Medicine, The Ohio State University Comprehensive Cancer Center, Columbus, OH

T

Torsten Haferlach

7Munich Leukemia Laboratory, Munich, Germany